Company Overview

IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body’s natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies.

Read More Corporate Presentation Corporate Fact Sheet

Latest News

IMUNON Presentation at World Vaccine & Immunotherapy Congress Highlights PLACCINE Preclinical Proof of Concept and Key Competitive Advantages

December 1, 2022

IMUNON to Participate in the A.G.P./Alliance Global Partners Virtual Biotech Conference on November 30, 2022 – December 1, 2022

November 22, 2022

IMUNON Announces Strategic Investment in Transomic Technologies

November 17, 2022

Financial Events

Imunon, Inc. Third Quarter 2022 Earnings Call

November 14, 2022 at 11:00 AM EST

Imunon Corporation Presentation_Chardan’s 6th Annual Genetic Medicines Conference

October 3, 2022 at 2:30 PM EDT